This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Watson Receives FTC Clearance For Actavis Acquisition

PARSIPPANY, N.J., Oct. 15, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that the Federal Trade Commission (FTC) has voted to approve Watson's acquisition of the Actavis group of companies.  The unanimous vote in support of the transaction follows Watson's agreement to a proposed consent order, pursuant to which Watson has agreed to divest certain products as a condition to obtaining FTC approval.  The parties have now obtained all regulatory approvals required to close the transaction.  Accordingly, the parties expect to consummate the acquisition in late October or early November.

Under the terms of the consent order with the FTC, Watson and Actavis have agreed to divest a number of marketed and pipeline products to Par Pharmaceutical Companies, Inc. and Sandoz.

Subject to the consummation of the transaction between Watson and Actavis, Par will acquire the following products:

  • Watson's Morphine Sulfate Extended Release Capsules
  • Actavis' Nifedipine Extended Release Tablets
  • Actavis' Metoclopramide Hydrochloride Tablets
  • Actavis' Fentanyl Transdermal Film
  • Actavis' Diltiazem Hydrochloride Extended Release Capsules

 

  • Watson's pending application for Adapalene/Benzoyl Peroxide Gel
  • Watson's pending application for Oxymorphone hydrochloride ER Tablets
  • Watson's pending application for Amphetamine Salts ER Tablets
  • Actavis' pending application for Rivastigmine Patch
  • Actavis' pending application for Glipizide Extended Release Tablets
  • Actavis' pending application for Varenicline Tartrate Tablets
  • Actavis' pending application for Oxycodone Hydrochloride Extended Release Tablets
  • Actavis' pending application for Ursodiol Tablets

 

  • Actavis' development stage Methylphenidate Hydrochloride Extended Release Tablets

Subject to the consummation of the transaction between Watson and Actavis, Sandoz will acquire the following products:

  • Actavis' Bupropion Hydrochloride 150 mg. Extended Release Tablets
  • Actavis' Lorazepam Tablets
  • Actavis' Diltiazem Hydrochloride Extended Release Capsules
  • Watson's pending application for Dextromethorphan Hydrobromide /Quinidine Sulfate




Stock quotes in this article: WPI 

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,441.51 +16.66 0.10%
S&P 500 1,864.56 +2.25 0.12%
NASDAQ 4,095.1080 +8.8830 0.22%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs